Compliance and adherence: Lifelong therapy for glaucoma

Alan Robin, Betsy Sleath, David Covert

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The Early Manifest Glaucoma Trial randomized those with early diagnosed previously untreated glaucoma into two groups: no treatment or treatment with a combination of laser trabeculoplasty plus betaxolol ophthalmic solution. At a median follow-up of 8 years, 67% of all subjects progressed and treatment significantly decreased the rate of progression. Despite the initially optimistic news, the results are not as encouraging as they might seem. As one might imagine, 76% of the control group progressed. However, despite apparent treatment, 59% of the treated glaucoma patients also progressed. One would like to know why more than 50% of those under treatment still experience additional glaucomatous progression.

Original languageEnglish (US)
Title of host publicationThe Glaucoma Book
Subtitle of host publicationA Practical, Evidence-Based Approach to Patient Care
PublisherSpringer New York
Pages651-656
Number of pages6
ISBN (Print)9780387766997
DOIs
StatePublished - Jan 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Robin, A., Sleath, B., & Covert, D. (2010). Compliance and adherence: Lifelong therapy for glaucoma. In The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care (pp. 651-656). Springer New York. https://doi.org/10.1007/978-0-387-76700-0_55